140 related articles for article (PubMed ID: 37672936)
1. Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.
Qian H; Hou C; Zhang Y; Ji S; Zhong C; Li J; Zhang Q; Huang J; Li C; ChengJi
Cancer Genet; 2023 Nov; 278-279():62-70. PubMed ID: 37672936
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
3. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J
BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571
[TBL] [Abstract][Full Text] [Related]
4. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
5. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
[TBL] [Abstract][Full Text] [Related]
6. MET overexpression correlated with prognosis of EGFR-mutant treatment‑naïve advanced lung adenocarcinoma: a real‑world retrospective study.
Wang N; Zhang Y; Wu J; Zhu Y; Wu Y; Huang B; Zhang R; Fan J; Nie X
Clin Transl Oncol; 2024 Jul; 26(7):1696-1707. PubMed ID: 38430418
[TBL] [Abstract][Full Text] [Related]
7. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
8. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
9. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
Kim IA; Lee JS; Kim HJ; Kim WS; Lee KY
BMC Cancer; 2018 Jul; 18(1):768. PubMed ID: 30055587
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment for postoperative recurrent EGFR-mutated lung adenocarcinoma: a multi-institutional retrospective study.
Miyata R; Hamaji M; Kawaguchi A; Shimazu Y; Ikeda M; Ishikawa M; Kayawake H; Menju T; Kobayashi M; Okumura N; Sakaguchi Y; Sonobe M; Matsumoto A; Shoji T; Katakura H; Sumitomo R; Huang CL; Takahashi M; Aoyama A; Muranishi Y; Kono T; Miyahara R; Date N; Fujinaga T; Miyamoto E; Nakagawa T; Fukada T; Sakai H; Date H
Eur J Cardiothorac Surg; 2022 Oct; 62(5):. PubMed ID: 35997576
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
12. Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.
Liang S; Wang H; Zhang Y; Tian H; Li C; Hua D
Cancer Med; 2024 Apr; 13(8):e7208. PubMed ID: 38659399
[TBL] [Abstract][Full Text] [Related]
13. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
[TBL] [Abstract][Full Text] [Related]
14. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
15. MET overexpression in EGFR L858R mutant treatment-naïve advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study.
Wang N; Zhu Y; Wu Y; Huang B; Wu J; Zhang R; Fan J; Nie X
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3219-3228. PubMed ID: 35904603
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
18. Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations.
Zhang G; Cheng R; Niu Y; Wang H; Yan X; Zhang M; Zhang X; Yang J; Wei C; Ma Z
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):651-657. PubMed ID: 36172729
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis.
Zhang R; Tian P; Chen B; Wang T; Li W
Postgrad Med; 2019 Apr; 131(3):199-206. PubMed ID: 30798634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
